BMS Resubmits Eliquis NDA, Gets Mid-March PDUFA Date
Bristol-Myers Squibb (BMS) and Pfizer have resubmitted their NDA for Eliquis to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.